Humankind Investments LLC Acquires 573 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Humankind Investments LLC grew its position in HCA Healthcare, Inc. (NYSE:HCA) by 15.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 4,317 shares of the company’s stock after purchasing an additional 573 shares during the period. Humankind Investments LLC’s holdings in HCA Healthcare were worth $1,296,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. FORA Capital LLC purchased a new stake in HCA Healthcare in the 4th quarter worth approximately $7,309,000. Clark Capital Management Group Inc. increased its stake in shares of HCA Healthcare by 17.1% in the 4th quarter. Clark Capital Management Group Inc. now owns 2,893 shares of the company’s stock valued at $868,000 after purchasing an additional 422 shares in the last quarter. Diligent Investors LLC boosted its position in HCA Healthcare by 110.6% during the fourth quarter. Diligent Investors LLC now owns 1,811 shares of the company’s stock worth $544,000 after purchasing an additional 951 shares in the last quarter. Consulta Ltd raised its stake in shares of HCA Healthcare by 100.0% during the 4th quarter. Consulta Ltd now owns 550,000 shares of the company’s stock worth $165,082,000 after buying an additional 275,000 shares during the period. Finally, Crestline Management LP raised its position in HCA Healthcare by 414.6% during the fourth quarter. Crestline Management LP now owns 4,117 shares of the company’s stock worth $1,236,000 after acquiring an additional 3,317 shares during the period. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Price Performance

NYSE:HCA opened at $353.85 on Friday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $417.14. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The business’s 50-day moving average price is $335.93 and its 200 day moving average price is $328.30. The firm has a market cap of $85.13 billion, a P/E ratio of 16.11, a PEG ratio of 1.10 and a beta of 1.46.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, April 25th. The company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.75 by $0.70. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. The business had revenue of $18.32 billion for the quarter, compared to the consensus estimate of $18.26 billion. During the same quarter in the previous year, the company posted $5.36 earnings per share. HCA Healthcare’s revenue for the quarter was up 5.7% compared to the same quarter last year. As a group, sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 16th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date is Monday, June 16th. HCA Healthcare’s payout ratio is 12.81%.

Insiders Place Their Bets

In other news, SVP Jennifer Berres sold 9,533 shares of HCA Healthcare stock in a transaction on Friday, February 14th. The stock was sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the sale, the senior vice president now owns 15,412 shares of the company’s stock, valued at approximately $4,971,757.08. This trade represents a 38.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

HCA has been the subject of several research reports. Barclays dropped their price target on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Baird R W cut shares of HCA Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price target on shares of HCA Healthcare in a report on Monday, January 27th. Robert W. Baird reaffirmed a “neutral” rating and set a $336.00 target price (down from $396.00) on shares of HCA Healthcare in a research note on Tuesday, April 15th. Finally, Royal Bank of Canada cut their price target on shares of HCA Healthcare from $384.00 to $376.00 and set an “outperform” rating for the company in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $381.13.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.